Organ transplantation represents a unique therapeutic option for irreparable organ dysfunction and rejection of transplants results from a breakdown in operational tolerance. Although endothelial cells (ECs) are the first target in graft rejection following kidney transplantation, their capacity to alloactivate and generate particular T lymphocyte subsets that could intervene in this process remains unknown. By using an experimental model of microvascular endothelium, we demonstrate that, under inflammatory conditions, human ECs induced proliferation of memory CD4 + CD45RA −
Organ transplantation represents a unique therapeutic option for irreparable organ dysfunction and rejection of transplants results from a breakdown in operational tolerance. Although endothelial cells (ECs) are the first target in graft rejection following kidney transplantation, their capacity to alloactivate and generate particular T lymphocyte subsets that could intervene in this process remains unknown. By using an experimental model of microvascular endothelium, we demonstrate that, under inflammatory conditions, human ECs induced proliferation of memory CD4 bright regulatory CD4 + T lymphocytes (Tregs). Although HLA-DR expression on resting microvascular ECs was sufficient to induce proliferation of memory CD4 + T cells, Treg amplification was dependent on the interaction with CD54, highly expressed only under inflammatory conditions. Moreover, expansion of Th17 cells was dependent on IL-6 and STAT-3, and inhibition of either specifically impaired Th17, without altering Treg expansion. Collectively these data reveal that the HLA-DR + ECs regulate the local inflammatory allogeneic response, promoting either an IL-6/STAT-3-dependent Th17 response or a contact-CD54-dependent regulatory response according to the cytokine environment. Finally, these data open therapeutic perspectives in human organ transplantation based on targeting the IL-6/STAT-3 pathway and/or promoting CD54 dependent Treg proliferation.
immune regulation | MHC class II T he allogeneic response to organ transplantation was initially considered to be predominantly mediated by the Th1 population whereas the Th2 population was believed to oppose Th1 cell activation, thus favoring graft survival (1) . Recent studies have identified additional CD4 + T cell subsets including IL-17-producing CD4 + T cells (Th17) and CD4 + FoxP3 + regulatory T cells (Tregs) (2) . A unique role for Th1 cells was excluded by using genetically deficient mice and T lymphocyte transfer experiments in MHC class II mismatched organ transplantation models (3, 4) . Th2 cytokines have been implicated in acute graft rejection (5) , and involvement of Th17 was shown in cardiac and lung allograft rejection (6, 7) . In the absence of a Th1 alloresponse, Th17 mediates a violent proinflammatory response, resulting in accelerated allograft rejection (6) . The Th1/Th2 paradigm is thus obsolete in models of organ transplantation. Recent studies have revealed reciprocal control of differentiation of proinflammatory Th17 and tolerogenic induced Treg subsets in mouse models (8) (9) (10) and in human studies (11) (12) (13) . Whether this equilibrium between Treg and Th17 subsets occurs in organ transplantation and, if so, can be skewed in one or other direction, is unknown.
In the context of organ transplantation, human endothelial cells (ECs) express MHC class I and class II molecules, and may therefore act both as stimulators of and targets for alloimmune responses (14) . ECs stimulate memory CD4 + T cell production of IFN-γ, thereby promoting a CD4 + Th1 profile (15) . EC allostimulation of CD4 + T cells requires expression of HLA-DR and the costimulatory molecule LFA-3 independently of CD80 and CD86 (16, 17) . ECs therefore have the potential to activate memory CD4 + T cells but their ability to orient the alloimmune response toward induced Treg-mediated tolerance or a proinflammatory effector response remains unknown. In MHC class II fully mismatched mouse models, vascular ECs activate and induce programmed death ligand 1 (PD-L1)-dependent Tregs, which inhibit in vitro and in vivo proliferation of alloreactive CD4 + T cells (18) . Human ECs express LFA-3 and PD-L1 (19) and we therefore investigated their ability to allostimulate CD4 + T cells and to generate regulatory or effector T cell populations. To address this question, we have studied the capacity of human microvascular ECs to stimulate HLA-DR-typed CD4 + T cells from allogeneic donors. The results reveal that human endothelium simultaneously generates proinflammatory Th17 and functional HLA-DR + Tregs under inflammatory conditions. These data lead to the suggestion that allograft endothelium participates in controlling CD4 + T lineage plasticity and can thus induce a regulatory or proinflammatory response, depending on the local cytokine microenvironment.
Results

HLA-DR Expression on Resting ECs Is Necessary and Sufficient to Induce CD4
+ T Cell Alloproliferation. The microvascular EC line HMEC-1 (20) constitutively expressed the costimulatory molecule LFA-3 whereas expression of HLA-DR was induced by activation with IFN-γ [activated ECs (aECs); Fig. 1A ]. In contrast with previous studies, ECs did not express the adhesion molecule CD54 in steady-state conditions (20) , although it was strongly expressed after activation with IFN-γ (Fig. 1A) . Constitutive expression of the costimulatory molecules LFA-3 and PD-L1 and the adhesion molecule VE-cadherin was unchanged by IFN-γ treatment (i.e., aECs; Fig. 1A and Fig. S1A ). To understand the role of HLA-DR in the absence of inflammatory stimuli, ECs were transduced with a lentiviral HLA-DR construct leading to constitutive surface expression of HLA-DR (ECsαβ) comparable to that of aECs. LFA-3 and VE-cadherin expression remained similar to that observed in resting ECs (Fig. 1A) . CD54 expression was induced in ECsαβ activated with IFN-γ (aECsαβ) to a similar level as that observed in aECs (Fig. 1A ). We next tested the ability of ECs and ECsαβ, activated with IFN-γ or not, to induce alloproliferation of CD4 + T cells. Fig. 1B shows that resting ECs failed to induce proliferation whereas resting ECsαβ constitutively expressing HLA-DR induced CD4 + T cell proliferation on day 7 (15.35 ± 4.56%), as did aECs (11.72 ± 4.16%) and aECsαβ (16.15 ± 3.32%). Proliferation is allorecognition-dependent as an HLA-DR-blocking antibody inhibits T cell proliferation by more than 70% (5.47 ± 3.31% at day 7 vs. 21.88 ± 8.81% with isotype IgG2a; P = 0.02; Fig. 1C) .
HLA-DR expression by resting ECs is therefore necessary and sufficient to induce CD4 + T cell alloproliferation.
Coculture of CD4 + T Cells with aECs Results in Selective Expansion of
Treg and Th17 Populations. We next determined whether aECs generated particular CD4 + T lymphocyte subsets. We compared the proportion of CD45RA
−
FoxP3
bright cells (i.e., Tregs) among CD4 + T cells on days 0 and 7 of culture. The percentage of Tregs was significantly increased (2.5 ± 1.08% of CD4 + T at day 7 vs. 1.13 ± 0.22% at day 0; P = 0.004; Fig. 2 Fig. 3A ; a representative cytofluorometric analysis of one allogeneic donor is shown in Fig. S2 ), whereas naive CD45RA + T cells did not proliferate, as previously reported (22) . This alloproliferative profile is specific to ECs, as professional antigen presenting cells induced equivalent proliferation of memory and Treg cells (Fig. 3A and Fig. S2 ). Moreover, the Treg response was observed only under inflammatory conditions, as resting ECsαβ induced comparable proliferation of memory and Treg cells [36 ± 11.34% vs. 30.67 ± 11.4%; P value not significant (NS)] and IFN-γ activation of ECsαβ restored the selective proliferation of Tregs (78.62 ± 10.13% vs. 22.45 ± 5.56% of memory T cells; P = 0.02).
We next examined whether aEC-induced alloproliferation of Tregs required soluble or contact-dependent inducible factors. Fig. 3B shows that contact inhibition in the presence of transwells abrogated Treg alloproliferation.
Based on the IFN-γ-induced expression of CD54 on aECsαβ, we examined the role of CD54 in Treg proliferation and/or expansion. CD54 blockade selectively inhibited Treg proliferation (39.88 ± 21.12% with α-CD54 vs. 68.12 ± 10.02% with IgG1; P = 0.02; Fig. 3C ) without modifying proliferation of the memory subset (23.95 ± 17.5% with α-CD54 vs. 31.5 ± 12.8% with IgG1; P value NS; Fig. 3C ). Moreover, inhibition of proliferation was associated with inhibition of Treg expansion in CD4 + T cell-aEC cocultures (1.07 ± 0.42% with α-CD54 vs. 2.45 ± 1.15% with IgG1; P = 0.007; Fig. 3C ). Similarly, CD54-expressing aECsαβ induced Treg expansion, unlike resting ECsαβ, which do not express CD54 (3.3 ± 0.53% vs. 1.17 ± 0.25%; P = 0.02; Fig. 3C ), and CD54 blocking inhibited expansion (1.75 ± 0.25% with α-CD54 vs. 3.12 ± 0.62% with IgG1; P = 0.02; Fig. 3C ).
Finally, coculture of CD4 + FoxP3 − with aECs did not generate CD4 + CD45RA − FoxP3 bright cells (Fig. 3D ), thus excluding conversion as the mechanism of expansion in this model. Collectively, these data indicate that Treg expansion by aECs is a result of their alloproliferation and requires CD4 + T cell interaction with CD54-expressing aECs.
IL-6 and STAT-3 Phosphorylation Are Selectively Required for Th17
Expansion. We next investigated the origin of the expansion of the Th17 population. IL-6 secretion by ECs was high and was increased threefold by EC activation (Fig. 4A) . We also identified significant phosphorylation of STAT-3 (P-STAT-3) in proliferating CD4 + T cells after 7 d of culture with aECs (20.27 ± 10.65% vs. 0.3 ± 0.11% in nonproliferating CD4 + T cells; P = 0.002; Fig. 4B ).
The role of IL-6 and P-STAT-3 in Th17 amplification was determined by coculturing aECs with allogeneic CD4 + T cells in the presence of an IL-6R blocking antibody or a P-STAT-3 inhibitor (cucurbitacin I) directed against Janus kinases (23) .
First, IL-6R blockade inhibited STAT-3 phosphorylation in CD4 + T cells cocultured with aECs (0.68 ± 0.43% with α-IL-6R at day 7 vs. 12.17 ± 4.17% with IgG1; P = 0.002; Fig. 4B ).
Second, memory T cell proliferation after coculture with aECs was selectively inhibited by IL-6R mAb (5.58 ± 7.17% vs. 37.3 ± 10.34% with IgG1; P = 0.002; Fig. 4C ) and by cucurbitacin I (10.7 ± 9% vs. 31.6 ± 9.84% with DMSO; P = 0.002), whereas Treg proliferation was unchanged by IL-6R mAb (46.5 ± 13.11% vs. 62.67 ± 10.69% with IgG1; P value NS) or cucurbitacin I (51.71 ± 19.67% vs. 60.22 ± 10.67% with DMSO; P value NS).
Finally, blocking IL-6R inhibited CD4 + IL-17 + cell expansion (1.76 ± 0.32% with α-IL-6R vs. 4 ± 0.86% with IgG1; P = 0.008; Fig. 4D ) without altering the proportion of Tregs (2.56 ± 0.55% of CD4 + T cells vs. 3.08 ± 0.45% with IgG1; P value NS), which remained significantly higher than on day 0 (P = 0.004; Fig. 4D pansion (4.23 ± 1.87% vs. 8.53 ± 3.9%; P = 0.04; Fig. 4D ) but not Treg expansion (1.71 ± 0.56% vs. 2.4 ± 0.9%; P value NS). Expansion of Th17 cells by aEC is thus IL-6/P-STAT-3-dependent and implicates memory CD4 + T cell proliferation. 
HLA-DR expression on CD4
+ CD25 bright T cells identifies mature, functionally distinct Tregs involved in contact-dependent in vitro suppression (24) . We therefore examined HLA-DR expression on Tregs expanded by EC allostimulation. As shown in Fig. 5A , Treg proliferation is associated with increased HLA-DR expression (80.2 ± 9.45% of proliferating Tregs vs. 46.28 ± 8.62% of nonproliferating Tregs; P = 0.002), leading to an enlarged proportion of HLA-DR-expressing Tregs (64.8 ± 3.5% vs. 45 ± 8.45%; P = 0.008; Fig. 5A bright T cells with more than 80% inhibition at a suppressor-to-responder ratio of 1:1 (mean, 80.6%; range, 88.7-76.2%; P < 0.05; Fig. 5B ) and as much as 60% inhibition at a ratio of 1:9 (mean, 67.3%; range, 47.3-68.4%; P < 0.05). aEC-expanded Tregs therefore significantly suppress alloproliferation of autologous CD4 + T cells. In addition, ECαβ-or aECαβ-activated Tregs equally suppress autologous CD4 + T cell proliferation induced by ECsαβ or aECsαβ, indicating that CD54 is not required for the suppressive function of Tregs induced by ECs (Fig. S3) .
Primary Microvascular ECs Induced Selective Expansion of Tregs and
Th17 Under Inflammatory Conditions. To further understand the ability of human microvascular ECs in expanding Th17 and Tregs under inflammatory conditions, we studied primary human dermal microvascular ECs (HMVECs). Similarly to HMEC-1, resting primary ECs constitutively expressed the costimulatory molecule LFA-3 and expression of HLA-DR and CD54 was strongly up-regulated by IFN-γ (Fig. 6A) .
Activated HMVECs (aHMVECs) induced alloproliferation of CD4 + T cells and selective proliferation of Tregs after 7 d of coculture (81.75 ± 7.54% of Tregs vs. 17.55 ± 6.31% of memory T cells; P = 0.02; Fig. 6B) .
Alloactivation was associated with the expansion of CD4 + IL-17 + (6.62 ± 3.54% at day 7 vs. 1.32 ± 0.38% at day 0; P = 0.008; Fig. 6C ) and CD4 + CD45RA
− FoxP3 bright cells (5.02 ± 1.9% at day 7 vs. 1.37 ± 0.38% at day 0; P = 0.02; Fig. 6C ).
These results suggest that the expansion of proinflammatory and regulatory T cell subsets is a general property of human microvascular ECs. 
Discussion
This study provides evidence for human EC expansion of proinflammatory and regulatory T cell subsets. In our experimental setting, Tregs and Th17 were increased in proliferating CD4 + T lymphocytes cocultured with allogeneic ECs. The model is relevant to human organ transplantation for two reasons. First, many previous studies examined the role of ECs from large vessels (namely human umbilical vein ECs) in T cell activation (16, 19) ; however, it is the microvasculature and not the macrovasculature that is implicated in the immune response that leads to allograft rejection. We therefore concentrated on microvascular ECs. Second, MHC class II and costimulatory molecule-expressing murine ECs cannot induce alloproliferation of CD4 + T lymphocytes (25) . Results from studies of murine microvascular endothelium are therefore difficult to extrapolate to human organ transplantation.
Human EC activation of memory CD4 + T cells, resulting in IL-2 secretion and proliferation (15, 22) , is dependent on HLA-DR and LFA-3 expression (16, 22) . This study reports that HLA-DR expression in resting human ECs is necessary and sufficient for CD4 + T cell alloproliferation whereas selective proliferation and expansion of Tregs occurs only in response to IFN-γ aECs. HLA-DR expression in ECs is thus insufficient to induce selective proliferation and expansion of Tregs.
Experiments with transwells revealed that Treg proliferation is contact-dependent, and a unique mechanism of Treg expansion dependent on CD54 expression by ECs was uncovered by the following observations: lack of increase of Tregs by ECs expressing HLA-DR but not CD54 (ECsαβ 
FoxP3
bright Tregs. CD54 interacts with LFA-1 on CD4 + T cells and enhances TCR engagement with MHC II-peptide ligand (27) . Given the known impairment of IL-2 production by CD4 + T cells in LFA-1-deficient mice (28) , defective Treg proliferation in the absence of CD54 may be caused by inadequate TCR activation and IL-2 production. CD54 has also been implicated in conversion of Th17 to a Treg phenotype by mesenchymal stem cells (29) . Thus, CD54 should be considered as an important protein for Treg development under certain conditions of inflammation.
Although PD-L1 has been involved in EC-mediated increased Treg suppression (30) , PD-L1 expression was unaltered by IFN-γ activation in our model and blocking PD-L1 expression did not alter the expansion of Tregs (Fig. S1B) .
HLA-DR expression on CD4 + CD25 bright FoxP3 bright cells defines a mature population of functional Tregs (24) . In our model, Treg expression of HLA-DR correlated with proliferation in response to aECs, suggesting that allostimulation promotes expansion of allospecific Tregs, and we have shown that their functional activity targeted the CD4 + T cell population that had initially alloproliferated in response to the same ECs.
The present study identifies a signaling profile for T cells alloactivated by IL-6-secreting ECs. IL-6 induced P-STAT-3 in proliferating cells, and inhibition of either IL-6R or P-STAT-3 disrupted memory T cell proliferation. Results of P-STAT-3 inhibition or IL-6R blockade indicate that aEC induction of Th17 cells is IL-6/P-STAT-3-dependent and implicates memory CD4 + T cell proliferation. Two IL-6-mediated mechanisms have been proposed: IL-6 conversion of Tregs into Th17 cells (10, 13) and IL-6 activation of STAT-3, which is required for memory T cell proliferation and survival (31) . Our results are consistent with the latter and lead to the suggestion that EC production of IL-6 in inflammatory conditions activates STAT-3 in memory T cells, thereby promoting proliferation of preformed Th17 cells. We have identified IL-6 as a key cytokine in human Th17 amplification within the context of memory T cell proliferation.
One limitation of our study was the variability in the frequencies of Tregs and Th17 induced by aECs between different donors. This variability is most likely a result of different degrees of CD4 + T allostimulation induced in the different donors by the same HLA-DR molecule. Indeed, Nadazdin et al. (32) reported that the frequency of allospecific memory T cells varied widely depending on the nature of the responder/stimulator MHC combination tested, even when fully MHC-mismatched combinations were studied. This suggests that certain MHC gene disparities are poorly immunogenic in selected responder/stimulator combinations.
Our data concord with the current concept of CD4 + T regulatory and proinflammatory lymphocyte plasticity (10) . Plasticity has been demonstrated in the tumor microenvironment (33) , and our data extend this finding to the environment of the allogeneic endothelium under inflammatory conditions such as those observed following organ transplantation.
Extrapolation of these data leads to the proposal that ECs of the engrafted organ orient graft-infiltrating T lymphocyte populations toward a proinflammatory or regulatory function and thus play a cardinal role in graft survival. We propose that, whereas cytokine secretion would enhance the local proinflammatory Th17 lymphocytes, a counterbalance would be provided by contactdependent expansion of regulatory T lymphocytes.
Finally, these data point to unique therapeutic targets in transplantation such as increasing expression of CD54 in ECs or inhibiting the IL-6/P-STAT-3 pathway to favor a regulatory rather than an inflammatory graft-infiltrating population under inflammatory conditions.
Methods
Cell Culture and Reagents. HMEC-1 was provided by A. Kesikli (University of Regensburg, Germany) and used between passages eight and 15 (33) . Primary ECs (i.e., HDMECs; Lonza) were used between passages three and six (34, 35) .
Lentiviral Constructs and HMEC-1 Transduction. The HLA-DR α and β cDNAs were amplified by PCR using the oligonucleotides 5′-AAAGGATCCATGGC-CATAAGTGGAGTC-3′ and 5′-AAACATATGTTACAGAGGCCCCCTGCG-3′ for HLA-DRα and 5′-AAAGGATCCATG GTGTGTCTGAAGCTC-3′ and 5′AAACA-TATGTCAGCTCACGAGTCCTGT-3′ for HLA-DRβ. PCR products were digested with BamHI and Nde I and cloned into the pWPXL lentiviral vector (Addgene) digested with BamHI and Nde I. HLADRβ1*11.02 lentiviral particles were produced by transfecting HEK293T cells by the calcium phosphate method with pWPXL-HLA-DR (α or β), packaging plasmid psPAX2, and envelope plasmid pMD2.G (Addgene), and harvesting supernatants after 48 h. Selected CD4 + T cells (Miltenyi Biotec) were stained with CD4-FITC, CD127-PE, and CD25-APC (BD Biosciences) before sorting on a FACSAria device (BD Biosciences).
Allostimulation Assays. CFSE-labeled PBMCs or CD4 + T cells (2.5 μM; Molecular Probes/Invitrogen) were stimulated with irradiated (20 Gy) ECs (1:1) for 7 d in RPMI-10% human AB serum (Biowest). ECs were activated with IFN-γ (100 UI/mL; R&D Systems) as indicated. Use of transwell inserts (4.26-mm diameter, 1-μm pore size; VWR) or pretreatment of HMEC-1 with CD54 (10 μg/mL; R&D Systems), PD-L1 (5 μg/mL; e-Bioscience), HLA-DR (10 μg/mL; clone L243) or mouse IgG antibodies before coculture are indicated. Cucurbitacin I (50 nM; Tocris Bioscience) or anti-IL-6R (10 μg/mL; R&D Systems) was added on day 0 of coculture.
Cytokine Detection by ELISA. Cytokines were measured in culture supernatants by using IL-1β, IL-6, TGF-β (BD Biosciences), IL-23 (Abcam), and IL-27 (R&D Systems) kits. 
